Survival outcomes with the use of surgery in limited‐stage small cell lung cancer
Authors:
Open Access
Abstract
BACKGROUND: Although chemotherapy and radiation therapy currently are recommended in limited‐stage small cell lung cancer (L‐SCLC), several small series have reported favorable survival outcomes in patients who underwent surgical resection. The authors of this report used a US population‐based database to determine survival outcomes of patients who underwent surgery.METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify patients who were diagnosed with L‐SCLC between 1988 and 2002 coded by SEER as localized disease (T1‐T2Nx‐N0) or regional disease (T3‐T4Nx‐N0). Kaplan‐Meier and Cox regression analyses were used to compare overall survival (OS) for all patients.RESULTS: In total, 14,179 patients were identified, including 863 patients who underwent surgical resection. Surgery was associated more commonly with T1/T2 disease (P < .001). Surgery was associated with improved survival for both localized disease and regional disease with improvements in median survival from 15 months to 42 months (P < .001) and from 12 months to 22 months (P < .001), respectively. Lobectomy was associated with the best outcome (P < .001). Patients with localized disease who underwent lobectomy with had a median survival of 65 months and a 5‐year OS rate of 52.6%; whereas patients who had regional disease had a median survival of 25 months and a 5‐year OS rate of 31.8%. On multivariate analysis, the benefit of surgery varied in a time‐dependant fashion. However, the benefit of lobectomy remained across all time intervals (P = .002).CONCLUSIONS: The use of surgery, and particularly lobectomy, in selected patients with L‐SCLC was associated with improved survival outcomes. Future prospective studies should consider the role of surgery as part of the multimodality management of this disease. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Impact of Postoperative Radiation Therapy on Survival in Patients With Complete Resection and Stage I, II, or IIIA Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results DatabaseJournal of Clinical Oncology, 2006
- Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)The Journal of Thoracic and Cardiovascular Surgery, 2005
- Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has comeThe Journal of Thoracic and Cardiovascular Surgery, 2005
- A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2004
- Surgical results for small cell lung cancer based on the new TNM staging systemThe Annals of Thoracic Surgery, 2000
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993
- Long term survival after pulmonary resection for small cell carcinoma of the lung.Thorax, 1989
- MEDICAL RESEARCH COUNCIL COMPARATIVE TRIAL OF SURGERY AND RADIOTHERAPY FOR PRIMARY TREATMENT OF SMALL-CELLED OR OAT-CELLED CARCINOMA OF BRONCHUSThe Lancet, 1973